These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 23095641

  • 1. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
    Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F.
    Cell Cycle; 2012 Nov 15; 11(22):4203-10. PubMed ID: 23095641
    [Abstract] [Full Text] [Related]

  • 2. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
    Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, Krishan A, Kurtoglu M, Chandna S, Aigner E, Datz C.
    Cell Cycle; 2009 Oct 01; 8(19):3149-56. PubMed ID: 19755849
    [Abstract] [Full Text] [Related]

  • 3. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
    Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F.
    Cell Cycle; 2012 Jul 01; 11(13):2518-25. PubMed ID: 22751419
    [Abstract] [Full Text] [Related]

  • 4. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S.
    Oncol Rep; 2013 Jul 01; 30(1):413-8. PubMed ID: 23624870
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
    Guo J, Schally AV, Zarandi M, Varga J, Leung PC.
    Reprod Biol Endocrinol; 2010 May 28; 8():54. PubMed ID: 20509930
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, Szalontay L, Lucci JA.
    Horm Metab Res; 2011 Oct 28; 43(11):816-20. PubMed ID: 22009378
    [Abstract] [Full Text] [Related]

  • 8. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Aug 28; 68(2):389-98. PubMed ID: 21046105
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, Ortmann O, Köster F, Buchholz S.
    Oncol Rep; 2008 Nov 28; 20(5):1289-94. PubMed ID: 18949435
    [Abstract] [Full Text] [Related]

  • 10. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
    Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G.
    Proc Natl Acad Sci U S A; 2007 Feb 06; 104(6):1943-6. PubMed ID: 17261802
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L.
    Prostate; 2013 Jun 06; 73(8):873-83. PubMed ID: 23280565
    [Abstract] [Full Text] [Related]

  • 12. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
    Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG.
    Cell Cycle; 2014 Jun 06; 13(17):2790-7. PubMed ID: 25486366
    [Abstract] [Full Text] [Related]

  • 13. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
    Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S, Seitz S.
    Proc Natl Acad Sci U S A; 2012 Jan 31; 109(5):1655-60. PubMed ID: 22307626
    [Abstract] [Full Text] [Related]

  • 14. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
    Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.
    Oncotarget; 2016 Aug 09; 7(32):52195-52206. PubMed ID: 27448980
    [Abstract] [Full Text] [Related]

  • 15. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G, Goulette FA, Darnowski JW, Calabresi P.
    Cancer Chemother Pharmacol; 2004 Mar 09; 53(3):261-6. PubMed ID: 14658007
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM.
    Int J Cancer; 2013 Feb 15; 132(4):755-65. PubMed ID: 22777643
    [Abstract] [Full Text] [Related]

  • 17. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G.
    J Clin Endocrinol Metab; 2001 May 15; 86(5):2144-52. PubMed ID: 11344219
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21.
    Wu HM, Schally AV, Cheng JC, Zarandi M, Varga J, Leung PC.
    Cancer Lett; 2010 Dec 01; 298(1):16-25. PubMed ID: 20630651
    [Abstract] [Full Text] [Related]

  • 19. Potentiating effects of GHRH analogs on the response to chemotherapy.
    Schally AV, Perez R, Block NL, Rick FG.
    Cell Cycle; 2015 Dec 01; 14(5):699-704. PubMed ID: 25648497
    [Abstract] [Full Text] [Related]

  • 20. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT.
    J Control Release; 2015 Feb 10; 199():72-83. PubMed ID: 25497312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.